Loading...
•
Sep 30, 2023
ALX Oncology Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Key Takeaways
ALX Oncology reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatment of advanced HER2-positive gastric/gastroesophageal junction (GEJ) cancer, completed a public offering generating gross proceeds of approximately $63.2 million, and realigned its leadership team.
Reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatment of advanced HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.
Completed public offering generating gross proceeds of approximately $63.2 million.
Realigned leadership team to match platform asset evorpacept’s maturing portfolio of programs and refined long-term development strategy.
Advanced pipeline of nine programs evaluating evorpacept in combination with anti-cancer antibodies, antibody-drug conjugates (“ADCs”), and PD-1/PD-L1 immune checkpoint inhibitors.
Forward Guidance
ALX Oncology believes its cash, cash equivalents, and investments along with the ability to draw down an additional $40 million of its term loan and the net proceeds from its recent public offering are sufficient to fund planned operations into early 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...